What are the pathophysiology, clinical manifestations, assessment methods, diagnostic studies, and management options for hypertrophic cardiomyopathy?

Hypertrophic Cardiomyopathy: Comprehensive Overview

Pathophysiology

HCM is fundamentally a genetic sarcomeric disease caused by mutations in cardiac sarcomere proteins, transmitted in an autosomal dominant pattern, with a prevalence of 1:500 1, 2. The molecular defect drives hypercontractility at the sarcomere level, which cascades into the characteristic pathophysiological features 3.

The core pathophysiological mechanisms include:

• Sarcomeric hypercontractility: Excessive actin-myosin interaction creates hyperdynamic ventricular function
• Left ventricular outflow tract obstruction (LVOTO): Dynamic obstruction occurs when gradients ≥30 mm Hg, primarily from systolic anterior motion (SAM) of the mitral valve; gradients ≥50 mm Hg are considered symptomatic 4
• Diastolic dysfunction: Results from impaired LV compliance due to hypertrophy and fibrosis, altered energetics, microvascular ischemia, and abnormal calcium reuptake; notably, diastolic abnormalities can manifest in young sarcomere gene carriers even before wall thickening develops 4
• Mitral regurgitation: Secondary MR from SAM (typically mid-to-late systolic, posterior/lateral jet) or primary leaflet abnormalities (excessive leaflet length, anomalous papillary muscle insertion) 4
• Arrhythmogenic substrate: Myocardial disarray and fibrosis create substrate for atrial fibrillation and ventricular arrhythmias

The obstruction is highly dynamic and sensitive to preload, afterload, contractility, heart rate, blood pressure, volume status, activity, medications, food, and alcohol intake 4.

Clinical Manifestations

Clinical presentations range from completely asymptomatic to severe heart failure and sudden cardiac death, with most symptomatic patients presenting with LVOTO 5.

Symptom Spectrum:

• Dyspnea on exertion: Most common symptom, related to LVOTO and/or diastolic dysfunction
• Chest pain: From microvascular ischemia despite normal coronary arteries
• Presyncope/syncope: Due to LVOTO, arrhythmias, or inadequate cardiac output with exercise
• Palpitations: From atrial fibrillation or ventricular arrhythmias
• Heart failure symptoms: Particularly in advanced disease with systolic dysfunction
• Sudden cardiac death: Can be the first manifestation, especially in young patients

Physical Examination Findings:

• Harsh systolic crescendo-decrescendo murmur at left sternal border that increases with Valsalva and standing (decreased preload), decreases with squatting (increased afterload)
• Bifid or triple apical impulse from forceful atrial contraction and early/late systolic bulges
• Paradoxically split S2 if severe obstruction
• S4 gallop from forceful atrial contraction against stiff ventricle

Disease Complications:

AF and heart failure have now emerged as the predominant causes of disease-related morbidity and mortality in adults, surpassing sudden death as the greatest unmet treatment need 4. This shift reflects successful SCD prevention strategies with ICDs.

Clinical Assessment

History Taking Priorities:

• Family history: Three-generation pedigree for HCM, sudden death, heart failure, arrhythmias (essential for genetic counseling) 1
• Symptom characterization: NYHA class, exercise tolerance, syncope/presyncope episodes, palpitations
• Cardiometabolic risk factors: Obesity, hypertension, diabetes, obstructive sleep apnea are highly prevalent and associated with poorer prognosis 4
• Medication response: Previous trials of beta-blockers, calcium channel blockers
• Activity level: Competitive sports participation (contraindicated in HCM)

Physical Examination Maneuvers:

• Valsalva maneuver: Increases gradient and murmur intensity
• Standing from squatting: Increases gradient
• Squatting from standing: Decreases gradient
• Post-premature ventricular contraction: Increases gradient (Brockenbrough sign)

Diagnostic Studies

Echocardiography (Primary Diagnostic Tool):

Transthoracic echocardiography is the cornerstone diagnostic modality 2, 6. Key assessments include:

• Wall thickness measurement: Unexplained LV wall thickness (typically asymmetric septal hypertrophy)
• LVOTO assessment:
  • Resting gradients in LVOT
  • Provocative maneuvers (standing, Valsalva, exercise) if resting gradient <30 mm Hg
  • Do NOT use dobutamine provocation due to lack of specificity 4
• SAM characterization: Timing, severity, mitral-septal contact
• Mitral regurgitation: Severity, mechanism (SAM vs. primary leaflet abnormality), jet direction
• Diastolic function: E/A ratio, E/e' ratio, left atrial size
• Obstruction site: Distinguish valvular, dynamic LVOT, fixed subvalvular, or midcavitary obstruction

Cardiac MRI:

Essential for definitive diagnosis when echocardiography is inconclusive and for tissue characterization 2, 7. Provides:

• Precise wall thickness measurements in all segments
• Late gadolinium enhancement (LGE): Identifies fibrosis, prognostic marker for adverse events
• Differential diagnosis: Excludes infiltrative diseases, storage disorders, athlete's heart
• Pre-procedural planning: Anatomy for septal reduction therapy

Electrocardiography:

• 12-lead ECG: Often abnormal with LV hypertrophy pattern, deep Q waves, T-wave inversions, left atrial enlargement
• Ambulatory monitoring (Holter/event monitor): Detect non-sustained ventricular tachycardia (NSVT), atrial fibrillation, conduction abnormalities

Exercise Testing:

• Cardiopulmonary exercise testing: Quantify functional capacity, assess for exercise-induced LVOTO, blood pressure response
• Exercise echocardiography: Measure provoked gradients, assess for dynamic obstruction

Genetic Testing:

Genetic testing should be considered for patients with primary HCM and is essential for family screening 1, 2. Key points:

• First-degree family member screening: Can begin at any age using genetic testing, serial imaging, or ECG surveillance
• Variant reconfirmation: Reported pathogenicity should be reconfirmed every 2-3 years as classifications evolve 1
• Specialized center involvement: Valuable for interpretation of variants of uncertain significance

Invasive Assessment:

• Cardiac catheterization: When clinical and echocardiographic findings are discordant, or to assess for coronary disease
• Hemodynamic assessment: Direct gradient measurement, assess diastolic dysfunction with filling pressures

Management

Risk Stratification for Sudden Cardiac Death

Assessing SCD risk is a critical management component that must integrate established risk markers with individual risk scores to facilitate shared decision-making regarding ICD placement 1.

Adult Risk Markers:

• Massive LV hypertrophy (≥30 mm)
• Family history of SCD
• Unexplained syncope
• NSVT on ambulatory monitoring
• Abnormal blood pressure response to exercise
• Extensive LGE on cardiac MRI (≥15% of LV mass)

Pediatric risk stratification differs fundamentally from adults, with different risk factor weights and components, varying with age and body size 1. Given the complexity of ICD placement in growing children, specialized HCM center consultation is essential.

Pharmacological Management

First-Line Therapy for Obstructive HCM:

For symptomatic patients with LVOT gradients ≥50 mm Hg, first-line treatment is non-vasodilating beta-blockers or non-dihydropyridine calcium channel blockers 2.

• Beta-blockers (preferred initial agent):

  • Lower LVOT gradient
  • Alleviate dyspnea
  • Improve quality of life
  • Common side effects: Bradycardia, hypotension, AV block risk

• Non-dihydropyridine calcium channel blockers (verapamil, diltiazem):

  • Lower LVOT gradient
  • Increase physical resilience
  • Verapamil specifically improves exercise capacity
  • Side effects: Bradycardia, hypotension, AV block risk

Avoid dihydropyridine calcium channel blockers and vasodilators as they can worsen LVOTO.

Cardiac Myosin Inhibitors (Novel Therapy):

Mavacamten is the only FDA-approved cardiac myosin inhibitor and represents a breakthrough for symptomatic obstructive HCM patients who do not achieve adequate relief from first-line therapy 1, 3.

• Mechanism: Directly inhibits actin-myosin interaction, decreasing cardiac contractility and reducing LVOTO at the molecular level
• Benefits:
  • Lowers LVOT gradient
  • Improves quality of life
  • Improves functional status and hemodynamic parameters
• Critical monitoring: 7-10% of patients experience reversible reduction of LVEF to <50% 2
• Absolute contraindication: Pregnancy due to teratogenic effects 1
• Represents mechanism-targeted therapy rather than just symptom management 3

Emerging Therapies:

• SGLT2 inhibitors: Demonstrate clinical benefits through improvements in myocardial energetics 3
• Gene-targeted therapies: Under active investigation, offering prospect of definitive cure 3

Invasive Septal Reduction Therapy

For patients with drug-refractory or severe LVOTO (gradients ≥50 mm Hg with persistent symptoms despite optimal medical therapy), invasive SRT performed by experienced HCM teams at dedicated centers provides safe and effective symptomatic relief 1, 4.

Surgical Septal Myectomy:

• Gold standard for septal reduction
• Allows direct visualization and correction of anatomic abnormalities
• Can address concomitant mitral valve abnormalities
• Requires cardiopulmonary bypass
• Outcomes significantly better at comprehensive HCM centers 1

Alcohol Septal Ablation:

• Percutaneous alternative to surgery
• Creates controlled myocardial infarction in targeted septal region
• Less invasive but less precise than surgery
• Risk of complete heart block requiring permanent pacemaker
• Must be performed at experienced centers

Pre-Procedural Requirements:

Close examination of mitral valve is mandatory to determine optimal invasive approach 4. Must distinguish:

• SAM-related MR (resolves with septal reduction)
• Primary leaflet abnormalities (may require concomitant mitral valve intervention)
• Obstruction site (LVOT vs. midcavitary)

Management of Complications

Atrial Fibrillation:

• High risk of thromboembolism
• Anticoagulation mandatory (CHA₂DS₂-VASc often underestimates risk in HCM)
• Rhythm control preferred when feasible
• Poor tolerance due to loss of atrial contribution to ventricular filling

Heart Failure:

• Now the predominant cause of morbidity and mortality 4
• Standard HF therapies with caution (avoid excessive afterload reduction)
• Consider advanced therapies including transplantation for end-stage disease
• Intensive cardiometabolic risk factor modification essential

ICD Therapy:

• Primary prevention in high-risk patients based on integrated risk assessment 1
• Shared decision-making incorporating patient's risk tolerance and treatment goals
• Secondary prevention for aborted SCD or sustained ventricular arrhythmias

Lifestyle Modifications

• Competitive sports participation is NOT indicated 1
• Intensive management of cardiometabolic risk factors (obesity, hypertension, diabetes, sleep apnea) 4
• Avoid dehydration and excessive alcohol
• Genetic counseling for family planning

Multidisciplinary Care Model

Although primary cardiology teams can initiate evaluation and treatment, referral to multidisciplinary HCM centers with appropriate expertise is important for optimizing care 1. Specialized center involvement is particularly critical for:

• Challenging treatment decisions with reasonable alternatives
• Weak recommendation strength (Class 2b)
• Genetic testing interpretation
• Primary prevention ICD decision-making
• HCM-specific invasive procedures (SRT)
• Pediatric HCM management

Pregnancy Considerations

• Mavacamten is absolutely contraindicated in pregnancy 1
• Most patients tolerate pregnancy well with careful monitoring
• Beta-blockers generally safe during pregnancy
• Increased hemodynamic monitoring required

Prognosis

With early diagnosis and guideline-directed management, patients with HCM have near-normal life expectancy and mortality <1% per year 2. The evolution from sudden death as the primary concern to heart failure and AF as the predominant causes of morbidity reflects successful risk stratification and ICD therapy, but highlights the ongoing need for comprehensive disease management beyond arrhythmia prevention 4.